Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Encelto Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy MP 5.01.679

    Encelto (revakinagene taroretcel-lwey) Coverage for MacTel Type 2

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.679 alerts

    Get alerted when Policy MP 5.01.679 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and coverage requirements for Encelto, a one-time implanted gene and cell therapy for adults with idiopathic macular telangiectasia type 2, subject to applicable Blue Cross of Idaho benefit-plan terms.

    Policy Summary
    PayerBluecross Idaho
    PolicyEncelto Coverage for MacTel Type 2
    Policy CodePolicy N/A
    Change TypeNew policyno material clinical or coverage changes
    Effective DateNovember 1, 2026
    Last ReviewJul 30, 2026
    Next Review DateN/A
    Key ActionConfirm all initial-treatment criteria are met and do not request repeat treatment after one implant per affected eye.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    21+Minimum age
    1 implant/eyeTreatment limit
    54 lettersBCVA threshold
    0.16–2.00 mm²Ellipsoid zone area

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Investigational
    Repeat treatment
    OutpatientListed care setting

    Coverage Criteria

    Initial treatment

    Encelto may be considered medically necessary for initial treatment when all of the following are met.

    Initial treatment requirements

    • At least one qualifying retinal finding: At least one of the following is present with fluorescein leakage typical of MacTel: hyperpigmentation outside a 500-micron radius from the center of the fovea; retinal opacification; crystalline deposits; right-angle vessels; or inner/outer lamellar cavities.At least 1 finding

    Not medically necessary or investigational

    Requests are considered not medically necessary or investigational when any of the following applies.

    Noncovered or investigational circumstances: The individual has previously received an Encelto implant in the affected eye; has exudative macular neovascularization, intraretinal neovascularization, or subretinal neovascularization; has received intravitreal steroid therapy or vascular endothelial growth factor inhibitors (anti-VEGFs) within the previous 3 months; has an active ocular and/or peri-ocular infection; is pregnant or plans to become pregnant; or does not meet the stated criteria or is requesting treatment for another indication.One or more conditions

    Coverage is excluded or considered not medically necessary when the individual has exudative macular neovascularization, intraretinal or subretinal neovascularization; has received intravitreal steroid therapy or anti-VEGF therapy within the previous 3 months; has an active ocular or peri-ocular infection; is pregnant or plans to become pregnant; or does not meet the applicable coverage criteria.

    Requests are not medically necessary when the affected eye has previously received an Encelto implant, when any listed neovascular condition or other exclusion is present, or when the initial-treatment requirements are not satisfied. Repeat treatment is considered investigational because safety and efficacy beyond one implant per eye have not been studied.

    Coding and Clinical Documentation

    HCPCSHCPCS
    J3403Revakinagene taroretcel-lwey, per implant
    CPTCPT
    No codes listed
    ICD-10-CMICD-10
    H35.071Retinal telangiectasis, right eye
    H35.072Retinal telangiectasis, left eye
    H35.073Retinal telangiectasis, bilateral
    H35.079Retinal telangiectasis, unspecified eye
    MacTel Diagnostic Retinal Findings
    Required leakageFluorescein leakage typical of MacTel
    Required retinal findingsAt least one qualifying finding: hyperpigmentation outside a 500-micron radius from the center of the fovea; retinal opacification; crystalline deposits; right-angle vessels; or inner/outer lamellar cavities
    Diagnostic contextMacTel type 2 in at least one eye
    Ellipsoid Zone Area
    Measurement rangeBetween 0.16 mm² and 2.00 mm²
    Measurement methodMeasured by spectral domain-optical coherence tomography (SD-OCT)

    Provider Actions and Denial Risks

    Denial Risk

    Review exclusions before requesting coverage

    Requests may be denied when the individual has a listed exclusion or does not meet the coverage criteria. Review the diagnosis, treatment history, infection status, pregnancy status, and all initial-treatment requirements before requesting Encelto.

    • Prior Encelto implant in the affected eye
    • Exudative, intraretinal, or subretinal neovascularization
    • Intravitreal steroid therapy or anti-VEGF therapy within the previous 3 months
    • Active ocular or peri-ocular infection
    • Pregnancy or plans to become pregnant
    • Failure to meet the stated coverage criteria
    Denial Risk

    Do not repeat treatment after implantation

    Do not request repeat Encelto treatment in an affected eye after a prior implant. Repeat treatment for any indication is considered investigational because safety and efficacy beyond one implant per eye have not been studied.

    Clinical Background

    Macular telangiectasia type 2 (MacTel) is a usually bilateral retinal neurodegenerative and vascular disorder that may cause progressive central vision loss. Encelto (revakinagene taroretcel-lwey) is a cell-based gene therapy delivered through a surgically implanted, semipermeable device that releases recombinant human ciliary neurotrophic factor to the retina. The policy describes Encelto as a one-time intravitreal implant; clinical trials demonstrated reduced loss of ellipsoid-zone area, while best-corrected visual acuity was essentially similar to sham treatment.

    Definitions

    Microperimetry
    Test typeA noninvasive visual field test
    What it measuresRetinal sensitivity
    How it assesses functionMeasures how well specific areas of the retina detect light stimuli
    Encelto
    Therapy typeCell-based gene therapy delivered via an implanted drug delivery system
    Cell and membrane designGenetically modified cells are encapsulated in a semipermeable hollow fiber membrane
    Implantation and mechanismThe device is implanted intravitreally, anchored to the sclera, and releases recombinant human ciliary neurotrophic factor (rhCNTF) to the retina

    Initial Therapy Criteria

    Initial treatment criteria

    Initial treatment may be considered medically necessary when all criteria are satisfied.

    Initial Encelto treatment criteria

    • Qualifying retinal finding: At least one of the following accompanies typical MacTel fluorescein leakage: hyperpigmentation outside a 500-micron radius from the center of the fovea; retinal opacification; crystalline deposits; right-angle vessels; or inner/outer lamellar cavities.At least 1 finding

    Continuation and Repeat Treatment

    No repeat treatment

    Repeat treatment is considered investigational for any indication.

    No repeat treatment: Do not repeat Encelto treatment in an affected eye after a prior Encelto implant. Safety and efficacy beyond one implant per eye have not been studied.Maximum 1 implant per affected eye

    Repeat treatment is considered investigational and may be denied.

    Quantity and Treatment Limits

    Encelto Quantity Limits
    Per-eye limitOne Encelto implant per affected eye
    Treatment frequencyOne-time treatment
    Repeat treatmentRepeat treatment for any indication is considered investigational because safety and efficacy beyond one implant per eye have not been studied

    Site of Care and Administration

    Note

    Use a qualified ophthalmologist for implantation

    Encelto is intended for surgical intravitreal implantation under aseptic conditions by a qualified ophthalmologist.

    • Perform the implantation surgically and intravitreally
    • Use aseptic conditions
    • Ensure the procedure is performed by a qualified ophthalmologist
    Billing Rule

    Office setting is an applicable place of service

    Outpatient physician office is a listed place of service for Encelto.

    • Place of service: outpatient physician office
    Policy Summary
    PayerBluecross Idaho
    PolicyEncelto Coverage for MacTel Type 2
    Policy CodePolicy N/A
    Change TypeNew policyno material clinical or coverage changes
    Effective DateNovember 1, 2026
    Last ReviewJul 30, 2026
    Next Review DateN/A
    Key ActionConfirm all initial-treatment criteria are met and do not request repeat treatment after one implant per affected eye.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical DocumentationProvider Actions and Denial RisksClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation and Repeat TreatmentQuantity and Treatment LimitsSite of Care and Administration
    Associated findingAn Inner Segment–Outer Segment Junction Line photoreceptor break in the affected eye(s)
    Best Corrected Visual Acuity
    Required score54 letters or better
    Snellen equivalent20/80 or better
    MeasureBest corrected visual acuity (BCVA)
    Recent Ocular Drug Therapy Exclusion
    Intravitreal steroid therapyMust not have occurred within the previous 3 months
    Anti-VEGF therapyMust not have occurred within the previous 3 months
    Exclusion statusRecent intravitreal steroid or anti-VEGF therapy may result in the request being considered not medically necessary
    • Maximum: one implant per affected eye
    • Repeat treatment may be denied
    Billing Rule

    Infusion clinic is an applicable place of service

    Infusion clinic is a listed place of service for Encelto.

    • Place of service: infusion clinic
    Billing Rule

    Home health is an applicable place of service

    Home health is a listed place of service for Encelto.

    • Place of service: home health